• +1-646-491-9876
    • +91-20-67278686

    Search

    Toll Like Receptor 3-Pipeline Review H1 2017

    Toll Like Receptor 3-Pipeline Review H1 2017

    • Report Code ID: RW0001834455
    • Category Pharmaceuticals
    • No. of Pages 69
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Toll Like Receptor 3 (CD283 or TLR3) - Pipeline Review, H1 2017

    Summary

    Toll Like Receptor 3 (CD283 or TLR3) pipeline Target constitutes close to 14 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report Toll Like Receptor 3 - Pipeline Review, H1 2017, outlays comprehensive information on the Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type.

    Toll Like Receptor 3 (CD283 or TLR3) - Toll-like receptor 3 (TLR3) is a protein encoded by the TLR3 gene. It control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR3 is a nucleotide-sensing TLR which is activated by double-stranded RNA, a sign of viral infection. It acts via the adapter TRIF/TICAM1, leading to NF-kappa-B activation, IRF3 nuclear translocation, cytokine secretion and the inflammatory response. The molecules developed by companies in Pre-Registration, Phase II, Preclinical and Discovery stages are 1, 3, 4 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Respiratory, Immunology, Gastrointestinal, Cardiovascular, Central Nervous System, Dermatology, Metabolic Disorders and Other Diseases which include indications Breast Cancer, Asthma, Autoimmune Disorders, Chronic Inflammation, Melanoma, Ovarian Cancer, Renal Cell Carcinoma, Acute Inflammation, Atherosclerosis, Bladder Cancer, Chronic Fatigue Syndrome (Myalgic Encephalomyelitis) , Chronic Obstructive Pulmonary Disease (COPD) , Colitis, Colon Cancer, Cutaneous T-Cell Lymphoma, Diabetic Foot Ulcers, Ebolavirus Infections (Ebola Hemorrhagic Fever) , Head And Neck Cancer Squamous Cell Carcinoma, Hepatitis B, Hepatitis C, Human Immunodeficiency Virus (HIV) Infections (AIDS) , Inflammation, Inflammatory Bowel Disease, Influenza A Virus, H5N1 Subtype Infections, Injury, Liver Cancer, Lymphoma, Merkel Cell Carcinoma, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Pandemic Influenza, Peritoneal Cancer, Pressure Ulcers, Prostate Cancer, Pulmonary Inflammation, Rhinovirus Infections, Sarcomas, Severe Acute Respiratory Syndrome (SARS) , Venous Leg Ulcers (Crural ulcer) , West Nile Virus Infections, Wounds and Zika Virus Infections.

    Furthermore, this report also reviewsalso reviews key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 3 (CD283 or TLR3)
    - The report reviews Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Toll Like Receptor 3 (CD283 or TLR3)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Toll Like Receptor 3 (CD283 or TLR3) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Toll Like Receptor 3 (CD283 or TLR3) - Overview
    Toll Like Receptor 3 (CD283 or TLR3) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Toll Like Receptor 3 (CD283 or TLR3) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Toll Like Receptor 3 (CD283 or TLR3) - Companies Involved in Therapeutics Development
    Hemispherx Biopharma Inc
    Innate Pharma SA
    Johnson & Johnson
    MultiCell Technologies Inc
    Oncovir Inc
    RMB-Research GmbH
    Toll Like Receptor 3 (CD283 or TLR3) - Drug Profiles
    Antibody to Antagonize TLR3 for Acute and Chronic Inflammatory Diseases - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CNTO-3157 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CU-CPT4a - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Drugs to Activate TLR3 for Atherosclerosis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IPH-33 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MCT-465 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Oligonucleotide to Agonize TLR3 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    P-7 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PEP-0202 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Poly-ICLC - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PrEP-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    rintatolimod - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Antagonize TLR-3 for Gastrointestinal Syndrome - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Statmicoll - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Toll Like Receptor 3 (CD283 or TLR3) - Dormant Products
    Toll Like Receptor 3 (CD283 or TLR3) - Discontinued Products
    Toll Like Receptor 3 (CD283 or TLR3) - Product Development Milestones
    Featured News & Press Releases
    May 31, 2017: Hemispherx Biopharma Repurposes Ampligen in Immuno-Oncology
    May 15, 2017: Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2017
    Mar 06, 2017: Hemispherx Biopharma Meets Ampligen Sales Milestone in the 1st Quarter of 2017
    Feb 09, 2017: hVIVO announces data from two Phase IIa clinical studies to further profile PrEP Biopharm's PrEP-001 as a potential prophylactic against the common cold
    Jan 26, 2017: Hemispherx Announces First Shipment of Newly Manufactured Rintatolimod (Ampligen) for Sale to Early Access Program in Europe
    Jan 11, 2017: Hemispherx Biopharma Announces Extension of Rintatolimod European Early Access Program (EAP) to Pancreatic Cancer Patients
    Oct 31, 2016: Hemispherx Biopharma Announces Identification of High Responder Patient Subgroup from Ampligen Phase III Trial in Patients with CFS/ME
    Oct 19, 2016: Hemispherx Biopharma Announces Completion of Ampligen Manufacturing Technology Transfer Milestone
    Aug 29, 2016: Hemispherx Biopharma to Present Data on the Activity of Ampligen Against Cancer at CHI's 4th Annual Immuno-Oncology Summit, August 29 through September 2, 2016 in Boston, MA
    Aug 23, 2016: Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic
    Jul 27, 2016: Hemispherx Biopharma Reaches Agreement with Avrio Biopharmaceuticals for the Accelerated Production of Ampligen
    Jul 25, 2016: Hemispherx Announces First Shipment of Rintatolimod (Ampligen) to Early Access Program in Europe
    Jun 14, 2016: hVIVO - Favourable results for PrEP Biopharms Flu Study
    Jun 07, 2016: Hemispherx Biopharma: Dr. William M. Mitchell Publishes Article Titled, "Efficacy of Rintatolimod in the Treatment of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) " in Expert Review of Clinical Pharmacology
    Jun 06, 2016: Hemispherx Biopharma Obtains a Comprehensive Carter Omnibus Assignment of Intellectual Property
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indications, H1 2017
    Number of Products under Development by Indications, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Indications, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products under Investigation by Universities/Institutes, H1 2017
    Products under Investigation by Universities/Institutes, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by Hemispherx Biopharma Inc, H1 2017
    Pipeline by Innate Pharma SA, H1 2017
    Pipeline by Johnson & Johnson, H1 2017
    Pipeline by MultiCell Technologies Inc, H1 2017
    Pipeline by Oncovir Inc, H1 2017
    Pipeline by RMB-Research GmbH, H1 2017
    Dormant Products, H1 2017
    Dormant Products, H1 2017 (Contd..1) , H1 2017
    Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Top 10 Indications, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Hemispherx Biopharma Inc
    Innate Pharma SA
    Johnson & Johnson
    MultiCell Technologies Inc
    Oncovir Inc
    RMB-Research GmbH

    Request for Sample

    Report Url http://www.reportsweb.com//toll-like-receptor-3-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//toll-like-receptor-3-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//toll-like-receptor-3-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments